Abstracts tagged "spondylarthritis and treatment"

Abstract Number: 665 • 2018 ACR/ARHP Annual Meeting
Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa
Clementina López-Medina¹, Anna Molto² and Maxime Dougados³, ¹Rheumatology Department, Cochin Hospital, Paris, France, ²Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ³Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France
Background/Purpose: Peripheral manifestations (arthritis, enthesitis and dactylitis) are frequent in patients with Spondyloarthritis (SpA). However, little is known regarding the impact of these manifestations on…
Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Andrea Shimabuco¹, Julio CB Moraes¹, Percival Sampaio-Barros², Cláudia Goldenstein-Schainberg¹, Celio R. Gonçalves¹, Ana CM Ribeiro¹ and Carla GS Saad¹, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
Abstract Number: 1624 • 2018 ACR/ARHP Annual Meeting
Real-World Insight into the Disease Burden and Treatment of Spondyloarthritis from a US-Based Life Impact Survey
James T. Rosenbaum¹, Lisa Pisenti², Yujin Park³ and Richard Howard⁴, ¹Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ²UCB, Inc., Smyrna, GA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Spondylitis Association of America, Van Nuys, CA
Background/Purpose: Spondyloarthritis (SpA) is a group of chronic, inflammatory diseases associated with severe pain in the joints and entheses. There is limited evidence on real-world…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 1517 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Rosa Expósito¹, Carlos M Gonzalez², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷ and Manuel Fernández⁸, ¹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain
Background/Purpose: Certolizumab pegol (CZP) is available for patients with spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axialSpA). CZP has a different molecular…
Abstract Number: 1519 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness in Radiographic and Non-Radiographic Axial Spondyloarthritis. a Natiowide Study
Carlos M Gonzalez¹, Rosa Expósito², Rosa García-Portales³, Ana Urruticoechea-Arana⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, José Santos Rey Rey⁷, Manuel Fernández⁸ and Mercedes Morcillo⁹, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ³Rheumatology, Hospital Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸H. Guadalajara, Guadalajara, Spain, ⁹Rheumatology, Hospital El Escorial, San Lorenzo de el Escorial, Spain
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. RAPID-axSpA trial investigated the efficacy and…
Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Julianna Hirsch¹, Michal Nudel², Shira Ginsburg³, Haya Hussein³, Karina Zilber³, Lisa Kaly³, Doron Rimar³, Nina Boulman³, Abid Awisat³, Hily Wollach², Michael Rozenbaum³, Itzhak Rosner³ and Gleb Slobodin³, ¹Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Haifa, Israel, ²Mifrakim Tz'eirim, Haifa, Israel, ³Bnai-Zion Medical Center, Haifa, Israel
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…
Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Leonieke van Mens¹, Simone Verweij², Arno van Kuijk³, Erik Stroes² and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Vascular Medicine, Academisch Medisch Centrum, Amsterdam, Netherlands, ³Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…
Abstract Number: 2618 • 2014 ACR/ARHP Annual Meeting
Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study
Denis Poddubnyy¹, Kay-Geert Hermann¹, Johanna Callhoff², Joachim Listing² and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany
Background/Purpose Ustekinumab – a fully human monoclonal antibody against interleukins 12 and 23 – has been shown to be effective in reduction of symptoms of…
Abstract Number: 2584 • 2014 ACR/ARHP Annual Meeting
Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis
Anna Dellyes¹, Pierre Lafforgue¹, Vincent Pradel² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille University, Marseille, France, ²Epidemiology, APHM, Aix Marseille University, Marseille, France
Background/Purpose Smoking has been reported as associated with increase disease activity, more functional impairment, poorer quality of life and more radiographic damages in patients (pts)…
Abstract Number: 2839 • 2013 ACR/ARHP Annual Meeting
Effects Of Treatment On Spinal Fat Lesions As Assessed By MRI With The Fat Spondyloarthritis Spine Score
Susanne Juhl Pedersen¹, Zheng Zhao², Stephanie Wichuk³, Robert GW Lambert⁴ and Walter P. Maksymowych³, ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ³Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Fat lesions develop after resolution of inflammation in the spine (1), and have also been shown to predict development of new syndesmophytes (2). Consequently,…
Abstract Number: 1798 • 2013 ACR/ARHP Annual Meeting
Ustekinumab For The Treatment Of Patients With Active Ankylosing Spondylitis: Results Of a 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS)
Denis Poddubnyy¹, Johanna Callhoff², Joachim Listing² and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany
Background/Purpose: In contrast to other inflammatory rheumatic diseases, such as rheumatoid arthritis, the therapeutic options in ankylosing spondylitis (AS) with predominant axial manifestations are limited…
Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting
Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial
In-Ho Song¹, Kay-Geert A. Hermann², Hildrun Haibel³, Christian Althoff⁴, Denis Poddubnyy³, Joachim Listing⁵, Anja Weiss⁶, Ekkehard Lange⁷, Bruce Freundlich⁸, Martin Rudwaleit⁹ and Joachim Sieper¹⁰, ¹Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶German Rheumatism Research Centre, Berlin, Germany, ⁷BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Endokrinologikum, Berlin, Germany, ¹⁰Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany
Background/Purpose: In patients with early axial spondyloarthritis (SpA) with a disease duration of
Abstract Number: 814 • 2013 ACR/ARHP Annual Meeting
Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Laura C. Coates^1,2, Anna R. Moverley^1,2, Lucy McParland³, Sarah Brown³, Howard Collier³, Jennifer Law³, Sarah R. Brown³, Neil Corrigan³, Nuria Navarro-Coy^3,4, Paul Emery^2,5, Philip G. Conaghan^1,2 and Philip S. Helliwell^1,6, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The aim of this study was to assess the impact of tight control of early psoriatic arthritis (PsA) in a randomised-controlled trial (RCT) using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].